http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2752528-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6636b59c3149a23a6ae7feaa3984d05f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C40B30-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C40B40-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B30-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B40-08 |
| filingDate | 2017-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d3dfc03ce090b68fd98089f4297f562 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b0ab2e7c7bc965cbf91bdc61593a7f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_400faa583116cb61b56d47a623a4d439 |
| publicationDate | 2021-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2752528-C2 |
| titleOfInvention | Compositions and libraries containing recombinant polynucleotides encoding t-cell receptors and methods for using recombinant t-cell receptors |
| abstract | FIELD: immune therapy. n SUBSTANCE: recombinant polynucleotide encoding alpha-chain and beta-chain of T-cell receptor (TCR) is proposed, wherein alpha-chain contains sequence SEQ ID NO: 1, and beta-chain contains sequence SEQ ID NO: 2. An expression vector encoding alpha-chain and beta-chain of T-cell receptor (TCR) is proposed, wherein alpha-chain contains sequence SEQ ID NO: 1, and beta-chain contains sequence SEQ ID NO: 2. A combination of two above-mentioned recombinant polynucleotides and a combination of two above-mentioned expression vectors are also proposed. A method for the prevention and/or therapy of an individual who has been diagnosed with, is suspected of having, or is at risk of developing or relapsing cancer is also proposed, which includes injection to an individual of modified human T-cells. Cancer includes cancer cells that express NY-ESO-1/LAGE-1 antigen. Human T-cells contain a) one expression vector containing recombinant polynucleotide encoding T-cell receptor (TCR) containing alpha-chain containing sequence SEQ ID NO: 1 and beta-chain containing sequence SEQ ID NO: 2; or b) two expression vectors, wherein one expression vector encodes alpha-chain containing sequence SEQ ID NO: 1, and the second expression vector encodes beta-chain containing sequence SEQ ID NO: 2. n EFFECT: group of inventions can be effectively used in adaptive immune therapy. n 12 cl, 10 dwg, 1 tbl, 2 ex |
| priorityDate | 2016-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1034.